A Study on the Effect and Safety of BAY 2927088 Tablets in Patients with Solid Tumors and HER2 Mutations
Summary description of the study
Researchers are looking for a better way to treat people with solid tumors and HER2-activating mutations. Before a treatment can be approved for use in humans, researchers conduct clinical trials to better understand its safety and effectiveness. In this study, the researchers want to find out how well BAY2927088 works in people with different types of solid tumors with HER2 mutations. This includes tumors in the colon or rectum, the uterus and cervix (lower part of the uterus), the bladder, as well as the biliary tract (including gallbladder and bile ducts) and other types of solid tumors, except for people with advanced non-small cell lung cancer (NSCLC).
Solid tumors may have specific changes or mutations in a gene called human epidermal growth factor receptor 2 (HER2). This leads to the formation of an abnormal form of the HER2 protein in the cancer cells, resulting in increased cell growth. The study treatment, BAY2927088, is intended to block the abnormal HER2 protein, which may potentially stop the spread of cancer. The study will include about 111 participants who are at least 18 years old. All participants will take 20 mg of BAY2927088 in the form of tablets. Participants will receive treatments in 3-week periods, called cycles. These 3-week cycles will be repeated throughout the study. Participants may take BAY2927088 until their cancer worsens, they experience medical problems, or they withdraw from the study.
(BASEC)
Intervention under investigation
Adult participants with metastatic or unresectable solid tumors with HER-2-activating mutations, including: colorectal, biliary, bladder, cervical, endometrial, and other solid tumor types.
Participants will receive BAY2927088 20 mg twice daily (BID) until disease progression according to RECIST 1.1, unacceptable toxicity, or until another withdrawal criterion is met.
RECIST 1.1 = Criteria for evaluating response in solid tumors, version 1.1
BID: twice daily
(BASEC)
Disease under investigation
various types of solid tumors with HER2 mutations
(BASEC)
- Documented histologically or cytologically confirmed locally advanced, unresectable or metastatic solid tumor disease (colorectal carcinoma; biliary tumor disease; bladder and urothelial tumor; cervical cancer; endometrial carcinoma; other solid tumor diseases, except for NSCLC).
- The participant must be ≥ 18 years old or have reached the legal minimum age for consent.
- Patients who have previously received an appropriate standard therapy for their tumor type and disease stage or for whom there are no satisfactory alternative treatments.
- Documented activating HER2 mutation.
- At least one measurable lesion that qualifies as a target lesion according to RECIST 1.1 criteria.
(BASEC)
Exclusion criteria
- Primary diagnosis of non-small cell lung cancer (NSCLC).
- Previous treatment with a HER2 tyrosine kinase inhibitor (TKI).
- Active brain metastases.
- Uncontrolled, severe comorbid condition.
(BASEC)
Trial sites
Bern, Geneva, Zurich
(BASEC)
Sponsor
Sophia Birnbaum Bayer (Schweiz) AG Medical Departement Bayer Schweiz, Pharmaceuticals Clinical Research Grubenstrasse 8 8045 Zurich
(BASEC)
Contact
Contact Person Switzerland
Sophia Birnbaum
+41 44 465 81 11
clinical.operations.switzerland@clutterbayer.comBayer (Schweiz) AG Medical Departement Bayer Schweiz, Pharmaceuticals Clinical Research Grubenstrasse 8 8045 Zurich
(BASEC)
Scientific Information
not available
Name of the authorising ethics committee (for multicentre studies, only the lead committee)
Ethics Committee Bern
(BASEC)
Date of authorisation
08.05.2025
(BASEC)
ICTRP Trial ID
not available
Official title (approved by ethics committee)
A Phase 2 open-label basket study to evaluate the efficacy and safety of orally administered reversible tyrosine kinase inhibitor BAY 2927088 (sevabertinib) in participants with metastatic or unresectable solid tumors with HER2-activating mutations (BASEC)
Academic title
not available
Public title
not available
Disease under investigation
not available
Intervention under investigation
not available
Type of trial
not available
Trial design
not available
Inclusion/Exclusion criteria
not available
not available
Primary and secondary end points
not available
not available
Registration date
not available
Incorporation of the first participant
not available
Secondary sponsors
not available
Additional contacts
not available
Secondary trial IDs
not available
Results-Individual Participant Data (IPD)
not available
Further information on the trial
not available
Results of the trial
Results summary
not available
Link to the results in the primary register
not available